非酒精性脂肪性肝病药物治疗进展

蒋艳明; 施军平

非酒精性脂肪性肝病药物治疗进展

1. 浙江中医药大学
2. 浙江中医药大学附属杭州第六医院中西医结合科

基金项目:

浙江省中医药计划科技项目(2008JA009)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 3472
- HTML全文浏览量: 13
- PDF下载量: 770
- 被引次数: 0
出版历程
- 出版日期: 2011-09-20

The progress of pharmacotherapy in non-alcoholic fatty liver disease

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是我国肝酶异常和慢性肝病的常见原因之一,其治疗包括控制饮食、运动锻炼和药物治疗。目前,临床上治疗NAFLD的药物包括减肥药、胰岛素增敏剂、抗氧化剂、抑制肾素血管紧张素系统的降压药、调脂药、细胞因子调节剂和具有良好前景的大麻素受体拮抗剂。在此对NAFLD治疗药物的近期发展作一综述。
- 脂肪肝 /
- 减肥药 /
- 二甲双胍 /
- 噻唑烷二酮类 /
- 受体,大麻酚 /
- 己酮可可碱
Abstract: Non-alcoholic fatty liver disease is one of the common reasons of chronic liver disease and leading liver enzyme abnormally in china.The treatment for NAFLD includes diet control, exercise and pharmacotherapy.At present, the drugs for NAFLD used in clinic include diet pill, insulin sensitizer, antioxidant, antihypertensive drug for suppressing the renin-angiotensin system, lipid-lowering drugs, cytokines-regulator agents the promising agent cannabinoid receptors antagonists.We will review the recent advances about the pharmacotherapy in non-alcoholic fatty liver disease here.
- fatty liver /
- anti-obesity agents /
- metformin /
- thiazolidinediones /
- receptors /
- cannabinoid

HTML全文

参考文献(24)

[1]Harrison SA, Fecht W, Brunt EM.Orlistat for overweightsubjects with non-alcoholic steat-ohepatitis:A random-ized, prospective trial[J].Hepatology, 2009, 49 (1) :80-86.

[2]Nar A, Gedik O.The effect of metformin on leptin in obesepatients with type 2 diabetes mellitus and nonalcoholic fattyliver disease[J].Acta Diabetol, 2009, 46 (2) :113-118.

[3]Raso GM, Esposito E, Iacono A, et al.Comparative thera-peutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat[J].Eur J Phar-macol, 2009, 604 (1-3) :125-131.

[4]Nobili V, Manco M, Ciampalini P, et al.Metformin use inchildren with nonalcoholic fatty liver disease:an open-label, 24-month, observational pilot study[J].Clin Ther, 2008, 30 (6) :1168-1176.

[5]Ratziu V, Charlotte F, Bernhardt C, et al.Long-term efficacyof rosiglitazone in nonalcoholic steatohepatitis:results of thefatty liver improvement by rosiglitazone therapy (FLIRT 2) ex-tension trial[J].Hepatology, 2010, 51 (2) :445-453.

[6]Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al.Impor-tance of changes in adipose tissue insulin resistance to histo-logical response during thiazolidinedione treatment of patientswith nonalcoholic steatohepatitis[J].Hepatology, 2009, 50 (4) :1087-1093.

[7]Harrison SA.Thiazolidinedione therapy for Nonalcoholic Steato-hepatitis:Go, Stop, or Proceed with Caution?[J].Hepatolo-gy, 2010, 51 (2) :366-369.

[8]Sanyal AJ, Chalasani N, Kowdley KV, et al.Pioglitazone, Vi-tamin E, or Placebo for Nonalc-oholic Steatohepatitis[J].N Engl J Med, 2010, 362 (18) :1675-1685.

[9]Mine T, Miura K, KajiokaT, et al.Nateglinide prevents fattyliver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet[J].Metabolism, 2008, 57 (1) :140-148.

[10]Rosselli MS, Burgue n~o AL, Carabelli J, et al.Losartan re-duces liver expression of plasmi-nogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liverdisease model[J].Atherosclerosis, 2009, 206 (1) :119-126.

[11]Yoshiji H, Noguchi R, Ikenaka Y, et al.Losartan, an angio-tensin-II type 1 receptor blocker, attenuates the liver fibro-sis development of non-alcoholic steatohepatitis in the rat[J].BMC Res Notes, 2009, 2:70.

[12]Fabbrini E, Mohammed BS, Korenblat KM, et al.Effect offenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoproteins kinetics, and insulin action inobese subjects with nonalcoholic fatty liver disease[J].ClinEndocrinol Metab, 2010, 95 (6) :2727-2735.

[13]Kondo K, SugiokaT, TsukadaK, et al.Fenofibrate, aperoxi-some proliferator-activated receptor alpha agonist, im-proves hepatic microcirculatory patency and oxygen availabili-ty in a high-fat-diet-induced fatty liver in mice[J].AdvExp Med Biol, 2010, 662:77-82.

[14]Matafome P, Nunes E, Louro T, et al.A role for atorvastatinand insulin combination in pro-tecting from liver injury in amodelof type2 diabetes with hyperlipidemia[J].Naunyn Schmi-edebergs Arch Pharmacol, 2009, 379 (3) :241-251.

[15]Nobili V, Manco M, Devito R.Lifestyle intervention and an-tioxidant therapy in children with nonalcoholic fatty liver dis-ease:a randomized, controlled trial[J].Hepatology, 2008, 48 (1) :119-128.

[16]Lee YM, Sutedja DS, Wai CT, et al.A randomized con-trolled pilot study of Pentoxifyllinein patients with non-alco-holic steatohepatitis (NASH) [J].Hepatol Int, 2008, 2 (2) :196-201.

[17]Abdelmalek MF, Sanderson SO, Angulo P, et al.Betaine fornonalcoholic fatty liver disease:results of a randomized pla-cebo-controlled trial[J].Hepatology, 2009, 50 (6) :1818-1826.

[18]Wu X, Zhang L, Gurley E, et al.Prevention of free fatty acid-induced hepatic lipotoxicity by 18 beta-glycyrrhetinic acidthrough lysosomal and mitochondrial pathways[J].Hepatol-ogy, 2008, 47 (6) :1905-1915.

[19]Tsujimoto T, Kawaratani H, KitazawaT, et al.Immunothera-py for nonalcoholic steato-hepatitis using the multiple cyto-kine production modulator Y-40138[J].World J Gastroen-terol, 2009, 15 (44) :5533-5540.

[20]中华医学会肝病学会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版) [J].中华肝脏病杂志, 2010, 18 (3) :163-166.

[21]Purohit V, RapakaR, Shurtleff D.Role of cannabinoids in thedevelopment of fatty liver (steatosis) [J].AAPS J, 2010, 12 (2) :233-237.

[22]Vemuri VK, Janero DR, Makriyannis A.Pharmaco therapeu-tic targeting of the endocannab-inoid signaling system:drugs for obesity and the metabolic syndrome[J].PhysiolBehav, 2008, 93 (4-5) :671-686.

[23]Gary-Bobo M, Elachouri G, Gallas JF, et al.Rimonabantreduces obesity-associated hepatic steatosis and featuresof metabolic syndrome in obese Zucker fa/farats[J].Hepa-tology, 2007, 46 (1) :122-129.

[24]Mallat A, Lotersztajn S.Endocannabinoids and their role infatty liver disease[J].Dig Dis, 2010, 28 (1) :261-266.

施引文献

资源附件(0)

访问统计